{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-017472","form_type":"8-K","ticker":"NTLA","cik":"0001652130","company_name":"Intellia Therapeutics, Inc.","filed_at":"2023-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.852291+00:00","generated_at":"2026-06-15T22:15:39.221762+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Intellia dosed first patient in NTLA-2002 Phase 2; Q1 net loss $103.1M, cash $1.2B","bullets":["Dosed first patient in global Phase 2 study of NTLA-2002 for HAE; enrollment completion expected 2H 2023.","Plans to submit IND in mid-2023 for global pivotal trial of NTLA-2001 for ATTR-CM; study initiation expected by year-end 2023.","Cash, cash equivalents and marketable securities of $1.2B as of March 31, 2023; net loss $103.1M for Q1 2023.","R&D expenses decreased to $97.1M from $133.1M YoY, partially due to absence of Rewrite acquisition expense.","Collaboration revenue increased to $12.6M from $11.3M; G&A expenses rose to $27.4M."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-017472","json":"https://secwatch.observer/filing/0000950170-23-017472.json","markdown":"https://secwatch.observer/filing/0000950170-23-017472.md","text":"https://secwatch.observer/filing/0000950170-23-017472.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1652130/000095017023017472/0000950170-23-017472-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1652130/000095017023017472/ntla-20230504.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T22:15:39.221762+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"39158ddeb1a55d810d2f86c6493f9ff9e138cacd","claim":"Intellia Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2023.","evidence_excerpt":"CAMBRIDGE, Mass., May 4, 2023 – Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today reported operational highlights and financial results for the first quarter ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1652130/000095017023017472/0000950170-23-017472-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}